What’s Next? Five Things To Look Out For In January
Viatris Gains Key Advantage For Interchangeable Insulin Biosimilar
Sun Pharma’s key antitrust trial kicks off and Lannett awaits word from the US FDA for its generic Advair filing during a busy first month of 2022, which also features updates from the annual J.P. Morgan Health Care Conference.
